HDAC6 and early-onset autosomal dominant Alzheimer disease: Thus, pharmacotherapy with HDAC6 inhibitors in animals simulating Alzheimer’s disease has demonstrated significant therapeutic potential due to the modulation of key links in the pathogenesis of this disease [78,79].